Compare DexCom, Inc. (DXCM) vs Zillow Group Inc Class C (Z) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Zillow Group Inc Class C — how do they compare? DexCom, Inc. trades at $84.11 (market cap $31.86B), while Zillow Group Inc Class C trades at $29.01 (market cap $6.59B). The key difference: DexCom, Inc. is far larger — about 4.8× Zillow Group Inc Class C's market cap, and DexCom, Inc. is trading nearer its 52-week high, Zillow Group Inc Class C nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Zillow Group Inc Class C for 38 Days on average.
| DXCM | Z | |
|---|---|---|
Market Cap | $31.86B | $6.59B |
Volume | 3,607,070 | 9,134,294 |
Sector | Health | Media |
52-Week High | $92.34 | $78.04 |
52-Week Low | $54.84 | $27.13 |
Typical Hold Time | 62 Days | 38 Days |
Enterprise Value | $31.32B | $6.47B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.41, showing modest daily gains of 0.13%. The stock demonstrates strong fundamental performance with consistent earnings beats and robust revenue growth, reaching $4.66 billion in 2025. Technical indicators show a bearish short-term trend with key support at $82. The company maintains impressive profitability with 20.12% net margins and 38.49% ROE, supported by growing adoption of CGM technology in diabetes care.
DXCM presents a compelling growth story with expanding market opportunities in Type 2 diabetes care. Analyst consensus remains strongly bullish with 81% buy ratings and $95.07 price target, suggesting 13% upside. Key risks include reimbursement challenges and competitive pressures. The company's strong cash flow generation and institutional support provide solid foundation for continued growth.
Zillow Group (Z) trades at $29.01, up 6.34% in the past 24 hours, showing strong momentum despite mixed technical signals. The company demonstrates improving fundamentals with revenue growth from $2.2B in 2024 to $2.6B in 2025 and a return to profitability with $23M net income. Recent earnings show two consecutive beats against expectations, though the stock faces headwinds from elevated mortgage rates and housing market volatility.
The outlook remains cautiously optimistic with analyst consensus price target of $60.33 suggesting significant upside potential. However, investors face risks from housing market sensitivity to interest rates and competitive pressures. The company's transition to an integrated transaction platform and AI integration present growth opportunities, but execution risks and market conditions warrant careful monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Zillow Group Inc Class C
Zillow Group is an online real estate company that simplifies buying, selling, renting, and financing properties. It partners with agents, brokers, and landlords, combining technology with quality service. Its brands include Zillow, Trulia, StreetEasy, and Hotpads.
Read more on Z →
